CEA-话题@MedSci

#CEA#

33篇内容 | 1854人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2200246, encodeId=900a2200246e2, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a> <a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=癌胚抗原CEA的上涨或下降可用来判断手术后肺癌的预后吗？这次有了研究数据！, objectType=article, longId=821992, objectId=72fa821992c9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=72fa821992c9, replyNumber=0, likeNumber=154, createdTime=2024-04-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=72fa821992c9, moduleTitle=癌胚抗原CEA的上涨或下降可用来判断手术后肺癌的预后吗？这次有了研究数据！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72fa821992c9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1488658, encodeId=2e2f1488658a1, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=Stroke：无症状颈动脉狭窄患者进行CABG合并CEA术的5年结果, objectType=article, longId=738902, objectId=db6ae389025e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db6ae389025e, replyNumber=0, likeNumber=95, createdTime=2022-09-12, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db6ae389025e, moduleTitle=Stroke：无症状颈动脉狭窄患者进行CABG合并CEA术的5年结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db6ae389025e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488657, encodeId=295a148865edd, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=AJNR：CEA后再狭窄的颈动脉血管壁MR特征有助于制订下一步治疗决策, objectType=article, longId=724973, objectId=011ee24973e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=011ee24973e7, replyNumber=0, likeNumber=81, createdTime=2022-04-27, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=011ee24973e7, moduleTitle=AJNR：CEA后再狭窄的颈动脉血管壁MR特征有助于制订下一步治疗决策, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=011ee24973e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488656, encodeId=76e9148865650, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=结直肠癌患者血清CEA.CA199的表达变化与肝转移的多因素相关性分析, objectType=article, longId=220687, objectId=3cd522068e08, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cd522068e08, replyNumber=0, likeNumber=79, createdTime=2021-11-22, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cd522068e08, moduleTitle=结直肠癌患者血清CEA.CA199的表达变化与肝转移的多因素相关性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cd522068e08)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488655, encodeId=5f7e1488655a5, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=Front Oncol：术前放疗(RT)和治疗前CEA水平跟局部晚期直肠癌（LARC）患者预后的关系, objectType=article, longId=218486, objectId=f89c21848669, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f89c21848669, replyNumber=0, likeNumber=83, createdTime=2021-10-14, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f89c21848669, moduleTitle=Front Oncol：术前放疗(RT)和治疗前CEA水平跟局部晚期直肠癌（LARC）患者预后的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f89c21848669)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488654, encodeId=e95e1488654b6, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=Front Oncol：围手术期不同时间点CEA水平跟II期结直肠癌患者生存的关系, objectType=article, longId=218424, objectId=a09d218424bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a09d218424bf, replyNumber=0, likeNumber=72, createdTime=2021-10-13, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a09d218424bf, moduleTitle=Front Oncol：围手术期不同时间点CEA水平跟II期结直肠癌患者生存的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a09d218424bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488653, encodeId=52221488653e4, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle= ACAS应该选择BMT还是CEA/CAS？, objectType=article, longId=215512, objectId=cc3e2155120c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc3e2155120c, replyNumber=0, likeNumber=88, createdTime=2021-08-11, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc3e2155120c, moduleTitle= ACAS应该选择BMT还是CEA/CAS？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc3e2155120c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488652, encodeId=21c91488652a7, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=Cancers：结直肠癌（CRC）患者辅助化疗后血浆中CEA, CA19-9, IL-6, CRP,和 YKL-40水平预测疾病进展的提前时间和预后作用, objectType=article, longId=215266, objectId=4d022152664b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d022152664b, replyNumber=0, likeNumber=71, createdTime=2021-08-05, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d022152664b, moduleTitle=Cancers：结直肠癌（CRC）患者辅助化疗后血浆中CEA, CA19-9, IL-6, CRP,和 YKL-40水平预测疾病进展的提前时间和预后作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d022152664b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488651, encodeId=8623148865150, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=Br J Cancer：癌胚抗原CEA：转移性结直肠癌患者诱导治疗后疾病进展的标志物, objectType=article, longId=214195, objectId=5bd121419591, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bd121419591, replyNumber=0, likeNumber=0, createdTime=2021-07-15, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bd121419591, moduleTitle=Br J Cancer：癌胚抗原CEA：转移性结直肠癌患者诱导治疗后疾病进展的标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bd121419591)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488650, encodeId=d7301488650b0, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=Clin Cancer Res：CEACAM7是CAR-T细胞治疗胰腺导管腺癌的有效靶点, objectType=article, longId=206165, objectId=19d8206165d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19d8206165d9, replyNumber=0, likeNumber=76, createdTime=2021-01-25, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19d8206165d9, moduleTitle=Clin Cancer Res：CEACAM7是CAR-T细胞治疗胰腺导管腺癌的有效靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19d8206165d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488649, encodeId=f0931488649d7, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=Clin Cancer Res：CEACAM5的调控及抗CEACAM5-SN38抗体-药物结合物在神经内分泌前列腺癌中的治疗效果 , objectType=article, longId=204057, objectId=4ed120405e9f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ed120405e9f, replyNumber=0, likeNumber=69, createdTime=2020-12-04, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ed120405e9f, moduleTitle=Clin Cancer Res：CEACAM5的调控及抗CEACAM5-SN38抗体-药物结合物在神经内分泌前列腺癌中的治疗效果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ed120405e9f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488648, encodeId=49c1148864878, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=Clin Cancer Res：新型抗体-药物耦联剂SAR408701治疗CEACAM5阳性上皮肿瘤的活性, objectType=article, longId=202096, objectId=825120209604, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=825120209604, replyNumber=0, likeNumber=83, createdTime=2020-10-15, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=825120209604, moduleTitle=Clin Cancer Res：新型抗体-药物耦联剂SAR408701治疗CEACAM5阳性上皮肿瘤的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=825120209604)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488647, encodeId=ab34148864e3b, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=研究性反义寡核苷酸疗法AKCEA-ANGPTL3-LRx治疗高甘油三酯血症取得阶段进展, objectType=article, longId=186957, objectId=f46318695ea5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f46318695ea5, replyNumber=0, likeNumber=58, createdTime=2020-01-31, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f46318695ea5, moduleTitle=研究性反义寡核苷酸疗法AKCEA-ANGPTL3-LRx治疗高甘油三酯血症取得阶段进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f46318695ea5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488646, encodeId=274c14886469a, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=因价格问题，英国NICE拒绝Akcea的反义寡链核苷酸药物Waylivra上市, objectType=article, longId=185670, objectId=0d8d1856e076, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d8d1856e076, replyNumber=0, likeNumber=129, createdTime=2020-01-05, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d8d1856e076, moduleTitle=因价格问题，英国NICE拒绝Akcea的反义寡链核苷酸药物Waylivra上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d8d1856e076)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488645, encodeId=cb39148864528, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=NEJM：反义寡核苷酸AKCEA-APO(a)-LRx可降低心血管疾病患者脂蛋白A水平, objectType=article, longId=185593, objectId=4513185593bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4513185593bd, replyNumber=0, likeNumber=74, createdTime=2020-01-04, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4513185593bd, moduleTitle=NEJM：反义寡核苷酸AKCEA-APO(a)-LRx可降低心血管疾病患者脂蛋白A水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4513185593bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488644, encodeId=f358148864457, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=Gastric Cancer：腹腔灌洗液中SYT13和CEA mRNA水平可以预测胃癌腹膜复发风险, objectType=article, longId=179123, objectId=66ea1e912320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66ea1e912320, replyNumber=0, likeNumber=62, createdTime=2019-09-10, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66ea1e912320, moduleTitle=Gastric Cancer：腹腔灌洗液中SYT13和CEA mRNA水平可以预测胃癌腹膜复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66ea1e912320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488643, encodeId=0f7e148864340, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=Aging Cell：衰老相关CEACAM1的信号传导促进血管功能障碍, objectType=article, longId=177454, objectId=182c1e7454f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=182c1e7454f8, replyNumber=0, likeNumber=80, createdTime=2019-08-13, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=182c1e7454f8, moduleTitle=Aging Cell：衰老相关CEACAM1的信号传导促进血管功能障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=182c1e7454f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488642, encodeId=90181488642c3, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=JCLA：循环CEA‐dNLR评分预测转移性胆囊癌患者的临床结果, objectType=article, longId=175345, objectId=2b931e53456c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b931e53456c, replyNumber=0, likeNumber=50, createdTime=2019-07-14, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b931e53456c, moduleTitle=JCLA：循环CEA‐dNLR评分预测转移性胆囊癌患者的临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b931e53456c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488641, encodeId=8dc51488641bf, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=Genocea宣布其个性化肿瘤新疫苗GEN-009的1/2a期临床试验的阳性数据, objectType=article, longId=166285, objectId=21951662856c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21951662856c, replyNumber=0, likeNumber=59, createdTime=2019-05-19, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21951662856c, moduleTitle=Genocea宣布其个性化肿瘤新疫苗GEN-009的1/2a期临床试验的阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21951662856c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488640, encodeId=02771488640cc, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, objectTitle=针对新型免疫检查点CEACAM1的单克隆抗体CM-24与Nivolumab联用的I/II期临床将开始, objectType=article, longId=164216, objectId=25ad16421626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ad16421626, replyNumber=0, likeNumber=68, createdTime=2019-04-15, rootId=0, userName=shizhenshan, userId=ce258462097, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ad16421626, moduleTitle=针对新型免疫检查点CEACAM1的单克隆抗体CM-24与Nivolumab联用的I/II期临床将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25ad16421626)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CEA

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #癌胚抗原# #CEA#

癌胚抗原CEA的上涨或下降可用来判断手术后肺癌的预后吗？这次有了研究数据！

2024-04-24发表于陕西省

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

Stroke：无症状颈动脉狭窄患者进行CABG合并CEA术的5年结果

2022-09-12

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

AJNR：CEA后再狭窄的颈动脉血管壁MR特征有助于制订下一步治疗决策

2022-04-27

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

结直肠癌患者血清CEA.CA199的表达变化与肝转移的多因素相关性分析

2021-11-22

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

Front Oncol：术前放疗(RT)和治疗前CEA水平跟局部晚期直肠癌（LARC）患者预后的关系

2021-10-14

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

Front Oncol：围手术期不同时间点CEA水平跟II期结直肠癌患者生存的关系

2021-10-13

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

ACAS应该选择BMT还是CEA/CAS？

2021-08-11

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

Cancers：结直肠癌（CRC）患者辅助化疗后血浆中CEA, CA19-9, IL-6, CRP,和 YKL-40水平预测疾病进展的提前时间和预后作用

2021-08-05

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

Br J Cancer：癌胚抗原CEA：转移性结直肠癌患者诱导治疗后疾病进展的标志物

2021-07-15

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

Clin Cancer Res：CEACAM7是CAR-T细胞治疗胰腺导管腺癌的有效靶点

2021-01-25

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

Clin Cancer Res：CEACAM5的调控及抗CEACAM5-SN38抗体-药物结合物在神经内分泌前列腺癌中的治疗效果

2020-12-04

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

Clin Cancer Res：新型抗体-药物耦联剂SAR408701治疗CEACAM5阳性上皮肿瘤的活性

2020-10-15

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

研究性反义寡核苷酸疗法AKCEA-ANGPTL3-LRx治疗高甘油三酯血症取得阶段进展

2020-01-31

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

因价格问题，英国NICE拒绝Akcea的反义寡链核苷酸药物Waylivra上市

2020-01-05

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

NEJM：反义寡核苷酸AKCEA-APO(a)-LRx可降低心血管疾病患者脂蛋白A水平

2020-01-04

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

Gastric Cancer：腹腔灌洗液中SYT13和CEA mRNA水平可以预测胃癌腹膜复发风险

2019-09-10

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

Aging Cell：衰老相关CEACAM1的信号传导促进血管功能障碍

2019-08-13

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

JCLA：循环CEA‐dNLR评分预测转移性胆囊癌患者的临床结果

2019-07-14

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

Genocea宣布其个性化肿瘤新疫苗GEN-009的1/2a期临床试验的阳性数据

2019-05-19

shizhenshan (审核中...)

前往app查看评论内容

#CEA#

针对新型免疫检查点CEACAM1的单克隆抗体CM-24与Nivolumab联用的I/II期临床将开始

2019-04-15

科室
- - 订阅+
  - 更多科室
工具
服务